Matrix metalloproteinases and atherogenesis in dependence of age

Gerontology

Volumn 53, Issue 2, 2007, Pages 63-73

  Kunz, Jochen ^a  

^a NONE   (Germany)

Author keywords

Atherosclerosis; Genetic variation; Matrix metalloproteinases; Matrix producing cells of vascular wall; Vascular extracellular matrix

Indexed keywords

MATRIX METALLOPROTEINASE;

ATHEROGENESIS; CELL FUNCTION; CELL PROLIFERATION; COLLAGEN DEGRADATION; GENE EXPRESSION; HUMAN; LIPID METABOLISM; NONHUMAN; PRIORITY JOURNAL; PROTEOGLYCAN SYNTHESIS; REVIEW; VASCULAR SMOOTH MUSCLE;

ADULT; AGED; AGED, 80 AND OVER; AGING; ANIMALS; ATHEROSCLEROSIS; EXTRACELLULAR MATRIX; HUMANS; MATRIX METALLOPROTEINASES; MICE; MIDDLE AGED; MUSCLE, SMOOTH, VASCULAR; PROTEOGLYCANS; TISSUE INHIBITOR OF METALLOPROTEINASES; TUNICA INTIMA; VARIATION (GENETICS);

EID: 33847125220     PISSN: 0304324X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000096351     Document Type: Review

References (131)

1. Steinberg D: Lipoproteins and the pathogenesis of atherosclerosis. Circulation 1987;76:508-514.
2. Ross R, Glomset JA: Atherosclerosis and the arterial smooth muscle cell. Proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science 1973;180:1332-1339.
3. Libby P: Inflammatory and immunomechanism in atherogenesis. Atheroscler Rev 1990;21:79-89.
4. Libby P, Aikawa M: Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med 2002;8:1257-1262.
5. Naghavi M, Libby P, Falk E: From vulnerable plaque to vulnerable patient. Circulation 2003;108:1664-1672, Part II: 1772-1778.
6. Buddecke E: Molekulare Medizin: eine systematische Einführung. Landsberg/Lech, ecomed 2002.
7. Kunz J: Pathologie der Arterienwand mit besonderer Berücksichtigung der Glykosaminoglykane. Berlin, VEB Verlag Volk und Gesundheit, 1975.
8. Raines EW: The extracellular matrix can regulate vascular cell migration, proliferation, and survival:relationships to vascular disease. Int J Exp Pathol 2000;81:173-182.
9. Wight TN, Merrilees MJ: Proteoglycans in atherosclerosis and restenosis: key roles for versikan. Circ Res 2004;94:1158-1167.
10. Galis ZS, Khatri JJ: Matrix metalloproteinases in vascular remodeling and atherogenesis. The good, the bad, and the ugly. Circ Res 2002;90:251-262.
11. Sternlicht MD, Werb Z: How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001;17:463-516.
12. Newby AC: Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev 2005;85:1-31.
13. Tziakas DN, Chalikias GK, Parissis JT: Serum profiles of matrix metalloproteinases and their tissue inhibitor in patients with acute coronary syndromes. The effects of short-term atorvastatin administration. Int J Cardiol 2004;94:269-277.
14. Stary HC: The sequence of cell and matrix changes in atherosclerotic lesions of coronary arteries in the first forty years of life. Eur Heart J 1990;11(suppl E):3-19.
15. Amorino GP, Hoover RL: Interactions of monocytic cells with human endothelial cells stimulate monocytic metalloproteinase production. Am J Pathol 1998;152:199-207.
16. Galt SW, Lindemann S, Medd D: Differential regulation of matrix metalloproteinase-9 by monocytes adherent to collagen and platelets. Circ Res 2001;89:509-516.
17. Moreau M, Brocheriou I, Petit L: Interleukin-8 mediates downregulation of tissue inhibitor of metalloproteinase-1 expression in cholesterol-loaded human macrophages: relevance to stability of atherosclerotic plaque. Circulation 1999;99:420-426.
18. Iivanainen E, Kahari VM, Heino J: Endothelial cell-matrix interactions. Microsc Res Tech 2003;60:13-22.
19. Mahoney WM, Schwartz SM: Defining smooth muscle cells and smooth muscle injury. J Clin Invest 2005;115:221-224.
20. Hendrix JA, Wamhoff BR, McDonald OG: 5′ CarG degeneracy in smooth muscle -actin is required for injury-induced gene suppression in vivo. J Clin Invest 2005;115:418-427.
21. Hedin U, Roy J, Tran PK: Control of smooth muscle cell proliferation in vascular disease. Curr Opin Lipidol 2004;15:559-565.
22. Mulvihill ER, Jaeger J, Sengupta R: Atherosclerotic plaque smooth muscle cells have a distinct phenotype. Arterioscler Thromb Vasc Biol 2004;24:1283-1289.
23. Sata M, Saiura A, Kunisato A: Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med 2002;8:403-409.
24. Yoshida T, Owens GK: Molecular determinants of vascular smooth muscle cell diversity. Circ Res 2005;96:280-291.
25. Hao H, Gabbiani G, Bochaton-Piallat ML: Arterial smooth muscle cell heterogeneity. Arterioscler Thromb Vasc Biol 2003;23:1510-1520.
26. Yu Gui and Zheng XL: Epidermal growth factor induction of phenotype-dependent cell cycle arrest in vascular smooth muscle cells is through the mitogen-activated protein kinase pathway. J Biol Chem 2003;278:53017-53025.
27. Braun-Dulleus RC, Mann MJ, Sedding DG: Cell cycle-dependent regulation of smooth muscle cell activation. Arterioscler Thromb Vasc Biol 2004;24:845-850.
28. Schrijvers DM, De Meyer GR, Kockx MM: Phagocytosis of apoptotic cells by macrophages is impaired in atherosclerosis. Arterioscler Thromb Vasc Biol 2005;25:1256-1261.
29. Martinet W, Schrijvers DM, De Meyer GR: Western array analysis of human atherosclerotic plaques: downregulation of apoptosislinked gene 2. Cardiovasc Res 2003;60:259-267.
30. Hartung D, Sarai M, Petrov A: Resolution of apoptosis in atherosclerotic plaque by dietary modification and statin therapy. J Nucl Med 2005;46:2051-2056.
31. Trion A, van der Laarse A: Vascular smooth muscle cells and calcification in atherosclerosis. Am Heart J 2004;147:808-814.
32. Hamacher S, Matern S, Roeb E: Extrazelluläre Matrix - von der Grundlagenforschung zur klinischen Bedeutung. Eine Übersicht unter besonderer Berücksichtigung der Matrix Metalloproteinasen. Dtsch Med Wochenschr 2004;129:1976-1980.
33. Iozzo RV: Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem 1998;67:609-652.
34. Kinsella MG, Bressler SL, Wight TN: The regulated synthesis of versican, decorin, and biglycan: extracellular matrix proteoglycans that influence cellular phenotype. Crit Rev Eukaryot Gene Expr 2004;14:203-234.
35. Labat-Robert J, Bihari-Varga M, Robert L: Extracellular matrix. FEBS Lett 1990;268:386-393.
36. Wight TN: Versican: a versatile extracellular matrix proteoglycan in cell biology. Curr Opin Cell Biol 2002;14:617-623.
37. O'Brien KD, Lewis K, Fischer JW: Smooth muscle cell biglycan overexpression results in increased lipoprotein retention on extracellular matrix: implications for the retention of lipoproteins in atherosclerosis. Atherosclerosis 2004;177:29-35.
38. Shimizu-Hirota R, Sasamura H, Kuroda M: Extracellular matrix glycoprotein biglycan enhances vascular smooth muscle cell proliferation and migration. Circ Res 2004;94:1067-1074.
39. Fischer JW, Steitz SA, Johnson PY: Decorin promotes aortic smooth muscle cell calcification and colocalizes to calcified regions in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2004;24:2391-2396.
40. Deb A, Skelding KA, Wang S: Integrin profile and in vivo homing of human smooth muscle progenitor cells. Circulation 2004;110:2673-2677.
41. Murata K, Motayama T, Kotake C: Collagen types in various layers of the human aorta and their changes with the atherosclerotic process. Atherosclerosis 1986;60:251-262.
42. Brasselet C, Durand E, Addad F: Collagen and elastin cross-linking: a mechanism of constrictive remodeling after arterial injury. Am J Physiol Heart Circ Physiol 2005;289:H2228-H2233.
43. Leask A, Abraham DJ: TGF-β signaling and the fibrotic response. FASEB J 2004;18:816-827.
44. Oemar BS, Werner A, Garnier JM: Human connective tissue growth factor is expressed in advanced atherosclerotic lesions. Circulation 1997;95:831-839.
45. Rodriguez-Feo JA, Sluijter JPG, de Kleijn DPV: Modulation of collagen turnover in cardiovascular disease. Curr Pharm Des 2005;11:2501-2514.
46. Kunz J: Initial Lesions of vascular aging disease (arteriosclerosis). Gerontology 2000;46:295-299.
47. Kunjathoor VV, Chiu DS, O'Brien KD: Accumulation of biglycan and perlecan, but not versican, in lesions of murine models of atherosclerosis. Arterioscler Thromb Vasc Biol 2002;22:462-468.
48. Chung IM, Gold SM, Schwartz SM: Enhanced extracellular matrix accumulation in restenosis of coronary arteries after stent deployment. J Am Coll Cardiol 2002;40:2072-2081.
49. Katsuda S, Kaji T: Atherosclerosis and extracellular matrix. J Atheroscler Thromb 2003;10:267-274.
50. Lindstedt KA, Leskinen MJ, Kovanen PT: Proteolysis of the pericellular matrix - a novel element determining cell survival and death in the pathogenesis of plaque erosion and rupture. Arterioscler Thromb Vasc Biol 2004;24:1350-1358.
51. Stegemann JP, Hong H, Nerem RM: Mechanical, biochemical, and extracellular matrix effects on vascular smooth muscle cell phenotype. J Appl Physiol 2005;98:2321-2327.
52. Heeneman S, Cleutjens JP, Faber BC: The dynamic extracellular matrix: intervention strategies during heart failure and atherosclerosis. J Pathol 2003;200:516-525.
53. Yang F, Zhao P, She M: The dynamic change of extracellular matrix in human coronary atherogenesis. Zhonghua Bing Li Xue Za Zhi 1998;27:177-181.
54. Bond M, Sala-Newby GB, Newby AC: Focal adhesion kinase (FAK)-dependent regulation of S-phase kinase-associated protein-2 (Skp-2) stability. A novel mechanism regulating smooth muscle cell proliferation. J Biol Chem 2004;279:37304-37310.
55. Schmidt R, Bultmann A, Ungerer M: Extracellular matrix metalloproteinase inducer regulates matrix metalloproteinase activity in cardiovascular cells: implications in acute myocardial infarction. Circulation 2006;113:834-841.
56. Yoon YW, Kwon HM, Hwang KC: Upstream regulation of matrix metalloproteinase by EMMPRIN; extracellular matrix metalloproteinase inducer in advanced atherosclerotic plaque. Atherosclerosis 2005;180:37-44.
57. Rajagopalan S, Meng XP, Ramasamy S: Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. J Clin Invest 1996;98:2572-2579.
58. Carmeliet P, Moons L, Herbert JM: Urokinase but not tissue plasminogen activator mediates arterial neointima formation in mice. Circ Res 1997;81:829-839.
59. Browatzki M, Larsen D, Pfeiffer CA: Angiotensin II stimulates matrix metallo-proteinase secretion in human vascular smooth muscle cells via nuclear factor-kappaB and activator protein 1 in a redox-sensitive manner. J Vasc Res 2005;42:415-423.
60. Death AK, Fisher FJ, McGrath KC: High glucose alters matrix metalloproteinase expression in two key vascular cells: potential impact on atherosclerosis in diabetes. Atherosclerosis 2003;168:263-269.
61. Feinberg MW, Jain MK, Werner F: Transforming growth factor-beta 1 inhibits cytokine-mediated induction of human metalloelastase in macrophages. J Biol Chem 2000;275:25766-25773.
62. Liu J, Xiong W, Baca-Regen L: Mechanism of inhibition of matrix metalloproteinase-2 expression by doxycycline in human aortic smooth muscle cells. J Vasc Surg 2003;38:1376-1383.
63. Yoshimura K, Aoki H, Ikeda Y: Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase. Nat Med 2005;11:1330-1338.
64. Chen F, Eriksson P, Hansson GK: Expression of metalloproteinase 9 and its regulator in the unstable coronary atherosclerotic plaque. Int J Mol Med 2005;15:57-65.
65. Perlstein TS, Lee RT: Smoking, metalloproteinases, and vascular disease. Arterioscler Thromb Vasc Biol 2006;26:250-256.
66. Lee RT, Schoen FJ, Loree HM: Circumferential stress and matrix metalloproteinase 1 in human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 1996;16:1070-1073.
67. Rasmussen LM, Hansen PR, Ledet T: Homocysteine and the production of collagens, proliferation and apoptosis in human arterial smooth muscle cells. APMIS 2004;112:598-604.
68. Kuzuya M, Kanda S, Sasaki T: Deficiency of gelatinase A supresses smooth muscle cell invasion and development of experimental intima hyperplasia. Circulation 2003;108:1375-1381.
69. Radhakrishnamurthy B, Srinivasan SR, Vijayagopal P: Arterial wall proteoglycans - biological properties related to pathogenesis of atherosclerosis. Eur Heart J 1990;11(suppl E):148-157.
70. Sukhova GK, Schonbeck U, Rabkin E: Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation 1999;99:2503-2509.
71. Molloy KJ, Thompson MM, Jones JL: Unstable carotid plaques exhibit raised matrix metalloproteinase-8 activity. Circulation 2004;110:337-343.
72. Annabi B, Shedid D, Ghosn P: Differential regulation of matrix metalloproteinase activities in abdominal aortic aneurysmas. J Vasc Surg. 2002;35:539-546.
73. Johnson C, Galis ZS: Matrix metalloproteinase-2 and -9 differentially regulate smooth muscle cell migration and cell-mediated collagen organization. Arterioscler Thromb Vasc Biol 2004;24:54-60.
74. Filippov S, Koenig GC, Chun T-H: MT1-matrix metalloproteinase directs arterial wall invasion and neointima formation by vascular smooth muscle cells. JEM 2005;202:663-671.
75. Oak MH, EL Bedoui J, Anglard P: Red wine polyphenolic compounds strongly inhibit pro-matrix metalloproteinase-2 expression and its activation in response to thrombin via direct inhibition of membrane type 1-matrix metalloproteinase in vascular smooth muscle cells. Circulation 2004;110:1861-1867.
76. Ergul A, Portik-Dobos V, Hutchinson J: Downregulation of vascular matrix metalloproteinase inducer and activator proteins in hypertensive patients. Am J Hypertens 2004;17:775-782.
77. Kangavari S, Matetzky S, Shah PK: Smoking increases inflammation and metalloproteinase expression in human carotid atherosclerotic plaques. J Cardiovasc Pharmacol Ther 2004;9:291-298.
78. Jormsjo S, Whatling C, Walter DH: Allelespecific regulation of matrix metalloproteinase-7 promoter activity is associated with coronary artery luminal dimensions among hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2001;21:1834-1839.
79. Humphries SE, Martin S, Cooper J: Interaction between smoking and the stromelysin-1 (MMP 3) gene 5A/6A promoter polymorphism and risk of coronary heart disease in healthy men. Ann Hum Genet 2002;66:343-352.
80. Pöllänen PJ, Lehtimäki T, Mikkelsson J: Matrix metalloproteinase 3 and 9 gene promoter polymorphisms: joint action of two loci as a risk factor for coronary artery complicated plaques. Atherosclerosis 2005;180:73-78.
81. Hofmann MA, Lalla E, Lu Y: Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J Clin Invest 2001;107:663-664.
82. Signorelli SS, Malaponte G, Libra M: Plasma levels and zymographic activities of matrix metalloproteinases 2 and 9 in type II diabetics with peripheral arterial disease. Vasc Med 2005;10:1-6.
83. Derosa G, Avanzini MA, Geroldi D: Matrix metalloproteinase 2 may be a marker of microangiopathy in children and adolescents with type 1 diabetes mellitus. Diabetes Res Clin Pract 2005;70:119-125.
84. Rodriguez-Pla A, Bosch-Gil JA, Rossello-Urgell J: Metalloproteinase-2 and -9 in giant cell arteritis: involvement in vascular remodeling. Circulation 2005;112:264-269.
85. Matsuyama A, Sakai N, Ishigami M: Matrix metalloproteinases as novel disease markers in Takayasu arteritis. Circulation 2003;108:1469-1473.
86. Park JA, Shin KS, Kim YW: Polymorphism of matrix metalloproteinase-3 promoter gene as a risk factor for coronary artery lesions in Kawasaki disease. J Korean Med Sci 2005;20:607-611.
87. de Leeuw K, Sanders JS, Stegeman C: Accelerated atherosclerosis in patients with Wegener's granulomatosis. Ann Rheum Dis 2005;64:753-759.
88. Zou CC, Zhao ZY, Tang LF: Plasma levels of matrix metalloproteinase-9 in Henoch-Schonlein purpura. Scand J Rheumatol 2006;35:52-55.
89. Beyzade S, Zhang S, Wong YK: Influences of matrix metalloproteinase-3 gene variation on extent of coronary atherosclerosis and risk of myocardial infarction. J Am Coll Cardiol 2003;41:2130-2137.
90. Liu PY, Chen JH, Li YH: Synergistic effect of stromelysin-1 (matrix metalloproteinase-3) promoter 5A/6A polymorphism with smoking on the onset of young acute myocardial infarction. Thromb Haemost 2003;90:132-139.
91. Ye S, Watts GF, Mandalia S: Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. Br Heart J 1995;73:209-215.
92. Ye S, Gale CR, Martyn CN: Variation in the matrix metalloproteinase-1 gene and risk of coronary heart disease. Eur Heart J 2003;24:1668-1671.
93. Blankenberg S, Rupprecht HJ, Poirier O: Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003;107:1579-1585.
94. Vascu A, Goldbergova M, Izakovicova HL: A haplotype constituted of four MMP-2 promoter polymorphisms (-1575G/A, -1306C/T, -790T/G and -735C/T) is associated with coronary triple-vessel disease. Matrix Biol 2004;22:585-591.
95. Loftus IM, Naylor AR, Bell PR: Matrix metalloproteinases and atherosclerotic plaque instability. Br J Surg 2002;89:680-694.
96. Arno G, Kaski JC, Smith DA: Matrix metalloproteinase-9 expression is associated with the presence of Chlamydia pneumoniae in human coronary atherosclerotic plaques. Heart 2005;91:521-525.
97. Kunz J: Chlamydia pneumoniae - ein vermuteter pathogenetischer Faktor der Koronararteriensklerose. Der Pathologe 1999;20:230-235.
98. Schmidt R, Redecke V, Breitfeld Y: EMMPRIN (CD 147) is a central activator of extracellular matrix degradation by Chlamydia pneumoniae-infected monocytes. Implications for plaque rupture. Thromb Haemost 2006;95:151-158.
99. Ogata T, Shibamura H, Tromp G: Genetic analysis of polymorphisms in biologically relevant candidate genes in patients with abdominal aortic aneurysms. J Vasc Surg 2005;41:1036-1042.
100. Eriksson P, Jormsjo-Pettersson S, Brady AR: Genotype-phenotype relationships in an investigation of the role of proteases in abdominal aortic aneurysm expansion. Br J Surg 2005;92:1372-1376.
101. Deguchi JO, Aikawa E, Libby P: Matrix metalloproteinase-13/collagenase-3 deletion promotes collagen accumulation and organization in mouse atherosclerotic plaques. Circulation 2005;112:2708-2715.
102. Silence J, Collen D, Lijnen HR: Reduced atherosclerotic plaque but enhanced aneurysm formation in mice with inactivation of the tissue inhibitor of metalloproteinase-1 (TIMP-1) gene. Circ Res 2002;90:897-903.
103. Itoh T, Ikeda T, Gomi H: Unaltered secretion of beta-amyloid precursor protein in gelatinase A (matrix metalloproteinase 2)-deficient mice. J Biol Chem 1997;272:22389-22392.
104. Zureik M, Beaudeux JL, Courbon D: Serum tissue inhibitors of metalloproteinases 1 (TIMP-1) and carotid atherosclerosis and aortic arteria stiffness. J Hypertens 2005;23:2263-2268.
105. Meaume S, Benetos A, Henry OF: Aortic pulse wave velocity predicts cardiovascular mortality in subjects >70 years of age. Arterioscler Thromb Vasc Biol 2001;21:2046-2050.
106. Kunz J: Can atherosclerosis regress? The role of the vascular extracellular matrix and the age-related changes of arteries. Gerontology 2002;48:267-278.
107. Medley TL, Kingwell BA, Gatzka CD: Matrix metalloproteinase-3 genotype contributes to age-related aortic stiffening through modulation of gene and protein expression. Circ Res 2003;92:1254-1261.
108. Yasmin, McEniery CM, O'Saughnessy KM: Variation in the human matrix metalloproteinase-9 gene is associated with arterial stiffness in healthy individuals. Arterioscler Thromb Vasc Biol 2006;26:1799-1805.
109. van Oostrom O, Velema E, Schoneveld AH: Age-related changes in plaque composition: a study in patients suffering from carotid artery stenosis. Cardiovasc Pathol 2005;14:126-134.
110. Ferroni P, Basili S, Martini F: Serum metalloproteinase 9 levels in patients with coronary artery disease: a novel marker of inflammation. J Investig Med 2003;51:295-300.
111. Zeng B, Prasan A, Fung KC: Elevated circulating levels of matrix metalloproteinase-9 and -2 in patients with symptomatic coronary artery disease. Intern Med J 2005;35:331-335.
112. Tayebjee MH, Lip GY, Tan KT: Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2 and CD40 ligand levels in patients with stable coronary artery disease. Am J Cardiol 2005;96:339-345.
113. Tayebjee MH, Tan KT, MacFadyen RJ: Abnormal circulating levels of metalloprotease 9 and its tissue inhibitor 1 in angiographically proven peripheral arterial disease: relationship to disease severity. J Intern Med 2005;257:110-116.
114. Wu TC, Leu HB, Lin WT: Plasma matrix metalloproteinase-3 level is an independent prognostic factor in stable coronary artery disease. Eur J Clin Invest 2005;35:537-545.
115. Janssens S, Lijnen HR: What has been learned about the cardiovascular effects of matrix metalloproteinnases from mouse models? Cardiovasc Res 2006;69:585-594.
116. Mizon-Gérard F, de Groote P, Lamblin N: Prognostic impact of matrix metalloproteinase gene polymorphisms in patients with heart failure according to the aetiology of left ventricular dysfunction. Eur Heart J 2004;25:688-693.
117. Roeb E, Matern S: Matrix-Metalloproteinasen und kolorektales Karzinom. Med Klin 2003;98:763-770.
118. Watanabe N, Ikeda U: Matrix metalloproteinases and atherosclerosis. Curr Atheroscler Rep 2004;6:112-120.
119. Beaudeux JL, Giral P, Bruckert E: Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives. Clin Chem Lab Med 2004;42:121-131.
120. Sakamoto K, Murata T, Chuma H: Fluvastatin prevents vascular hyperplasia by inhibiting phenotype modulation and proliferation through extracellular signal-regulated kinase 1 and 2 and p38 mitogen activated protein kinase inactivation in organ-cultured artery. Arterioscler Thromb Vasc Biol 2005;25:327-333.
121. Senokuchi T, Matsumura T, Sakai M: Statins suppress oxidized low density lipoprotein-induced macrophage proliferation by inactivation of the small G protein-p38 MaPK pathway. J Biol Chem 2005;280:6627-6633.
122. Williams JK, Sukhova GK, Herrington DM: pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol 1998;31:684-691.
123. Puddu P, Cravero E, Puddu GM: Genes and atherosclerosis: at the origin of the predisposition. Int J Clin Pract 2005;59:462-472.
124. Ye S: Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcome. Cardiovasc Res 2006;69:636-645.
125. Bond M, Chase AJ, Baker AH: Inhibition of transcription factor NF-κB reduce matrix metalloproteinase-1, -3 and -9 production by vascular smooth muscle cells. Cardiovasc Res 2001;50:556-565.
126. Galis ZS, Sukhova GK, Lark MW: Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994;94:2493-2503.
127. Galis ZS, Johnson C, Godin D: Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling. Circ Res 2002;91:852-859.
128. George SL: Therapeutic potential of matrix metalloproteinase inhibitors in atherosclerosis. Expert Opin Investig Drugs 2000;9:993-1007.
129. Kinsella MG, Tran PK, Weiser-Evans MC: Changes in Perlecan expression during vascular injury: role in the inhibition of smooth muscle cell proliferation in the late lesion. Arterioscler Thromb Vasc Biol 2003;23:608-614.
130. Luan Z, Chase AJ, Newby AC: Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol 2003;23:769-775.
131. Laurent S, Boutouyrie P, Lacolley P: Structural and genetic bases of arterial stiffness. Hypertension 2005;45:1050-1055.